1. WHO. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996–2004. Geneva, World Health Organization, 2005.
http://www.who.int/malaria/publications/atoz/whohtmmal20051103/en/
. Accessed 29 Mar 2017.
2. WHO. Global report on antimalarial efficacy and drug resistance: 2000–2010. Geneva, World Health Organization, 2010.
http://www.who.int/malaria/publications/atoz/9789241500470/en/
. Accessed 29 Mar 2017.
3. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5:e128.
4. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14:982–91.
5. Commons RJ, Thriemer K, Humphreys G, Suay I, Sibley CH, Guerin PJ, et al. The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials. Int J Parasitol. 2017;7:181–90.